Immunovant, Inc. Share Price

Immunovant, Inc. Share Price

NASDAQ: IMVT | Mid Cap
$33.23
-$0.04 (-0.12%) Last updated on 18 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Immunovant, Inc. Stock Performance

Open
$33.10
Prev. Close
$33.27
Circuit Range
N/A
Day Range
$32.52 - $33.51
Year Range
$21.91 - $45.26
Volume
60,220
Average Traded
$33.16

Immunovant, Inc. Share Price Today

As of 18 November 2026, Immunovant, Inc.'s share price is $33.23. The stock opened at $33.10, compared to its previous close of $33.27. During today's trading session, Immunovant, Inc.'s share price traded between $32.52 and $33.51, with an average price of $33.02. Over the past 52 weeks, the stock has recorded a high of $45.26 and a low of $21.91. In terms of performance, Immunovant, Inc.'s share price has declined by 0.12% over the last six months and is up 37.48% on a year-on-year basis.

Immunovant, Inc. Share Price Chart

Line chart of the Immunovant, Inc. price trend over the selected period. The price fell overall, ranging from 32.48 to 33.66, ending at 33.23.
$32.52$33.51
L
Show Current Price
H

Immunovant, Inc. Stock Fundamentals & Key Indicators

Market Cap
$5.04B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.46
Revenue (TTM)
$0.00
Return On Equity (TTM)
-77.47%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
12.10%

Immunovant, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$110.64-$147.86-$153.22-$97.25
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-33.64%-3.63%36.53%

Immunovant, Inc. Annual Profit & Loss

All figures in USD

Particulars2023202420252026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$210.96-$259.34-$413.84-$505.61
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-22.93%-59.57%-22.18%

About Immunovant, Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Immunovant, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$29.60
$33.22
+14.14%
Oct 2026
$34.09
$29.10
-13.91%
Sep 2026
$40.52
$33.80
-22.86%
Aug 2026
$38.32
$43.81
+13.39%
Jul 2026
$38.55
$38.64
+0.23%
Jun 2026
$32.75
$38.55
+15.87%
May 2026
$27.41
$33.27
+22.54%
Apr 2026
$25.04
$27.15
+9.21%
Mar 2026
$27.11
$24.86
-10.41%
Feb 2026
$25.80
$27.75
+6.63%
Jan 2026
$25.68
$26.02
+2.42%
Dec 2025
$23.86
$25.41
+5.13%

IMVT Share Price FAQs